Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study

Objectives

To determine the effectiveness of enzyme replacement therapies (ERT) for adults with Gaucher disease (GD).

Design

A longitudinal, multi-centre cohort study, including prospective and retrospective clinical data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Treated patients contributed data before and during treatment. Untreated patients contributed natural history data.

Participants

Consenting adults (N?=?150, aged 16 to 83 years) with a diagnosis of GD who attended a specialist treatment centre in England. At recruitment, 131 patients were receiving ERT (mean treatment duration, 10.8 years; range 0–18 years).

Outcome measures

Clinical outcomes chosen to reflect disease progression, included platelet count; haemoglobin; absence/presence of bone pain; spleen and liver volumes and AST levels.

Results

One hundred and fifty adults were recruited. Duration of ERT was associated with statistically significant improvements in platelet count (p?p?p?p?=?0.02).

Conclusions

These data provide further evidence of the long-term effectiveness of ERT in adults with GD.